Hood River Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$62.8M Buy
371,503
+5,327
+1% +$920K 0.63% 53
2025
Q4
$66.9M Buy
366,176
+6,219
+2% +$868K 0.73% 53
2025
Q3
$43.7M Sell
359,957
-11,147
-3% -$1.26M 0.52% 67
2025
Q2
$38.7M Buy
+371,104
New +$39.3M 0.54% 65
2025
Q1
Sell
-644,785
Closed -$54.6M 147
2024
Q4
$54.6M Buy
644,785
+19,701
+3% +$1.81M 0.81% 45
2024
Q3
$56.2M Buy
625,084
+76,018
+14% +$6.64M 0.91% 42
2024
Q2
$44.2M Buy
549,066
+28,316
+5% +$2.1M 0.92% 38
2024
Q1
$41.6M Buy
520,750
+127,997
+33% +$10.7M 0.93% 39
2023
Q4
$31.3M Buy
392,753
+9,477
+2% +$634K 0.86% 46
2023
Q3
$26.8M Sell
383,276
-1,085
-0.3% -$81.1K 0.86% 51
2023
Q2
$27.6M Buy
384,361
+3,539
+0.9% +$261K 0.82% 55
2023
Q1
$23.5M Sell
380,822
-79,473
-17% -$5.22M 0.76% 51
2022
Q4
$35.5M Buy
+460,295
New +$27.5M 1.29% 29

Other funds holding AXSM

Hood River Capital Management's AXSM Position: Q1 2026 in Review

Hood River Capital Management increased its Axsome Therapeutics (AXSM) stake by 1.5% in Q1 2026, buying an estimated $920K and bringing the position to 371,503 shares worth $62.8M. The position accounts for 0.63% of the portfolio, ranked #53.

Hood River Capital Management first reported a position in AXSM in Q4 2022 and has held it in 13 quarters since. The position peaked at $66.9M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Hood River Capital Management held 371,503 shares of Axsome Therapeutics worth $62.8M as of Q1 2026.
  • Hood River Capital Management bought 5,327 Axsome Therapeutics shares in Q1 2026, an estimated $920K.
  • Axsome Therapeutics made up 0.63% of Hood River Capital Management's portfolio in Q1 2026, its #53 holding.
  • Hood River Capital Management first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 13 quarters since.
  • Hood River Capital Management's Axsome Therapeutics position peaked at $66.9M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Hood River Capital Management's 13F filing for Q1 2026, filed 15 May 2026.